About Cipla Pharmaceuticals Limited
Data last updated:
Cipla Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Cipla Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 November 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH2019PLC333266. Its GSTIN is 27AAICC4784A1ZP (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹190 Cr and a paid-up capital of ₹170 Cr. It is led by directors including Naveen Kapil (Managing Director) and Dinesh Ramniranjan Jain.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Tower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.19 Cr, a decline of 19% compared to the previous year. For the same year it recorded a net loss of ₹1.93 Cr (net margin -88.3%) and EBITDA of -₹70.71 Lakh (EBITDA margin -32.3%). Revenue has grown at a compounded annual rate (CAGR) of 87% over three years and 168% over five years.
The company has about 61 employees on its provident fund (EPFO) records.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cipla.com.
Company details
Contact details
Cipla Pharmaceuticals Limited's registered office is in Mumbai, Maharashtra. Its website is cipla.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressTower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Cipla Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Cipla Pharmaceuticals Limited
FY 2025 filings availableCipla Pharmaceuticals Limited reported revenue of ₹2.19 Cr (down 19% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 19% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 168%. EBITDA fell 136% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹70.71 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.93 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -32.3% | ||||
| Net Profit Margin | -88.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cipla Pharmaceuticals Limited, buy the company report.
Board of directors of Cipla Pharmaceuticals Limited
Cipla Pharmaceuticals has 4 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Dinesh Ramniranjan Jain Also directs: Aspergen Limited, Meditab Specialities Limited, Jay Precision Pharmaceuticals Private Limited and 2 more | Director | 19 Nov 2019 | 6 Years 11 Months | Current |
| Naveen Kapil | Managing Director | 13 Mar 2025 | 1 Years 7 Months | Current |
| Rajendra Kumar Chopra Also directs: Meditab Specialities Limited, Medispray Laboratories Private Limited, Cipla Digital Health Limited and 3 more | Director | 19 Nov 2019 | 6 Years 11 Months | Current |
| Raju Sunil Mistry | Additional Director | 23 Jul 2025 | 1 Years 3 Months | Current |
Auditor
Cipla Pharmaceuticals Limited is audited by Walker Chandiok & Co LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2023 | 001076N/N500013 |
Shareholding
The shareholding of Cipla Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Cipla Pharmaceuticals Limited, buy the company report.
Legal cases
No court or tribunal cases involving Cipla Pharmaceuticals Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Cipla Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Cipla Pharmaceuticals Limited has a workforce of 61 employees on its EPFO records as of Apr 07, 2025, across 1 active EPFO establishment.
GST
Cipla Pharmaceuticals has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAICC4784A1ZP | Maharashtra | Active | 25 Nov 2020 |
| 23AAICC4784A1ZX | Madhya Pradesh | Active | 25 Jan 2020 |
To see the full GST registrations and return filing status of Cipla Pharmaceuticals Limited, buy the company report.
Recent activity
Cipla Pharmaceuticals Limited has 11 board changes on record since 2019: 5 appointments and 6 cessations. The latest: Raju Sunil Mistry was appointed as Additional Director on 23 Jul 2025.
2 earlier events are in the company report.
News
Frequently asked questions
Cipla Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 November 2019 (7+ years old) and is registered under CIN U24239MH2019PLC333266.
Cipla Pharmaceuticals has 4 current directors:
- Naveen Kapil - Managing Director
- Dinesh Ramniranjan Jain - Director
- Rajendra Kumar Chopra - Director
- Raju Sunil Mistry - Additional Director
The latest financial statements of Cipla Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Cipla Pharmaceuticals is 27AAICC4784A1ZP, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 23AAICC4784A1ZX (Madhya Pradesh).
The CIN (Corporate Identification Number) of Cipla Pharmaceuticals is U24239MH2019PLC333266. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cipla Pharmaceuticals was incorporated on 19 November 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
Raju Sunil Mistry was appointed as Additional Director on 23 Jul 2025. Naveen Kapil was appointed as Managing Director on 13 Mar 2025. Naveen Kapil ceased to be Additional Director on 15 Jan 2025. Cipla Pharmaceuticals has 11 board changes on record in total.
Cipla Pharmaceuticals can be reached through the website cipla.com. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Cipla Pharmaceuticals is at Tower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
Cipla Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.